Janssen

J&J pharma segment poised with over 10 potential new product filings by 2017

Friday, May 24, 2013 01:28 PM

At a meeting with industry analysts, senior leaders from the Janssen Pharmaceutical companies of Johnson & Johnson announced they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017.

More... »

Janssen Biotech’s Simponi receives FDA approval for ulcerative colitis

Monday, May 20, 2013 08:00 AM

The FDA has approved Janssen Biotech’s Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.

More... »

FDA approves Janssen’s Invokana for type 2 diabetes

Monday, April 1, 2013 02:15 PM

The FDA has approved Janssen Pharmaceuticals’ Invokana (canagliflozin) for the treatment of adults with type 2 diabetes.

More... »

Janssen launches global cardiovascular research program, five new studies

Friday, March 8, 2013 10:47 AM

Janssen Research & Development has launched EXPLORER, a comprehensive, global research program for XARELTO (rivaroxaban), an oral anticoagulant. The program includes studies that will evaluate XARELTO for investigational use in patients with chronic heart failure and in those with coronary artery disease or peripheral artery disease.

More... »

GNS Healthcare joins Orion Bionetworks to develop predictive models

Monday, March 4, 2013 02:08 PM

GNS Healthcare has joined in the formation of Orion Bionetworks. This unique alliance will work to transform understanding of and accelerate the drug development process for a wide variety of diseases, beginning with multiple sclerosis (MS).

More... »

Abbott, Janssen, Pharmacyclics to develop companion test for leukemia therapy

Friday, February 22, 2013 11:16 AM

Global healthcare company Abbott has formed a collaboration with Janssen Biotech and Pharmacyclics, a biopharmaceutical company based in Sunnyvale, Calif., to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.

More... »

Janssen, Bayer, Portola form clinical collaboration

Friday, February 8, 2013 11:17 AM

Janssen Pharmaceuticals has signed a clinical collaboration agreement with Portola Pharmaceuticals and Bayer HealthCare to evaluate the safety of PRT4445—an investigational-stage antidote for Factor Xa inhibitors—in healthy volunteers who have been administered the oral anticoagulant Xarelto (rivaroxaban). The study will evaluate several dosage strengths of PRT4445 and its ability to reverse the anticoagulant activity of Xarelto in emergency situations.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

Janssen Labs at San Diego adds concept lab, open collaboration space

Wednesday, February 6, 2013 10:43 AM

Janssen Labs at San Diego, part of Janssen Research & Development, is adding a concept lab and an open collaboration space, just one year after opening.

More... »

Idenix Pharmaceuticals cancels IDX184 and IDX19368 programs for HCV

Wednesday, February 6, 2013 09:45 AM

Idenix Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the company had previously filed an IND but had not initiated patient dosing.

More... »